Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 89 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2014', provides an overview of the Chemotherapy Induced Nausea and Vomiting's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Nausea and Vomiting and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chemotherapy Induced Nausea and Vomiting products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Nausea and Vomiting pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chemotherapy Induced Nausea and Vomiting Overview 8
Therapeutics Development 9
Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Overview 9
Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis 10
Chemotherapy Induced Nausea and Vomiting - Therapeutics under Development by Companies 11
Chemotherapy Induced Nausea and Vomiting - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Chemotherapy Induced Nausea and Vomiting - Products under Development by Companies 17
Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development 18
Acacia Pharma Ltd. 18
Aphios Corporation 19
BioDelivery Sciences International, Inc. 20
Genovate Biotechnology Co., LTD. 21
Helsinn Holding S.A. 22
Heron Therapeutics, Inc. 23
INSYS Therapeutics, Inc. 24
Kyowa Hakko Kirin Co., Ltd. 25
Merck & Co., Inc. 26
RedHill Biopharma Ltd. 27
Shin Nippon Biomedical Laboratories, Ltd. 28
Suda Ltd 29
Teikoku Pharma USA, Inc. 30
Tesaro, Inc. 31
Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 41
(netupitant + palonosetron hydrochloride) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
APD-403 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
APD-421 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
aprepitant - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
aprepitant - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
dronabinol - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
dronabinol - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
granisetron - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
granisetron - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
granisetron - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
granisetron ER - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
granisetron ER - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ondansetron hydrochloride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ondansetron hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ondansetron hydrochloride CR - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rolapitant hydrochloride - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
TPW-146 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Chemotherapy Induced Nausea and Vomiting - Recent Pipeline Updates 64
Chemotherapy Induced Nausea and Vomiting - Dormant Projects 77
Chemotherapy Induced Nausea and Vomiting - Discontinued Products 78
Chemotherapy Induced Nausea and Vomiting - Product Development Milestones 79
Featured News & Press Releases 79
Nov 06, 2014: Heron Therapeutics Discloses HTX-019 Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV 79
Nov 06, 2014: Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV 79
Oct 10, 2014: FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy 80
Sep 27, 2014: Rolapitant Reduces Nausea and Vomiting in Phase III Trial 81
Sep 08, 2014: OPKO Licensee TESARO Submits New Drug Application for Rolapitant 81
Jul 10, 2014: Helsinn Announces That Phase 2/3 Pivotal Trials for NEPA (netupitant 300mg + oral palonosetron 0.50mg), Will be Published in the Annals of Oncology 82
Jul 08, 2014: Insys Therapeutics Updates Timing of NDA for Dronabinol Oral Solution 83
Jun 30, 2014: Merck Announces Data from Investigational Phase 3 Study on EMEND (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Children Undergoing Emetogenic Chemotherapy 84
Jun 02, 2014: Heron Therapeutics Provides Update on SUSTOL Program 85
Jun 01, 2014: Tesaro Summarizes Phase 3 Rolapitant Data Presented at the 2014 American Society of Clinical Oncology Annual Meeting and Provides an Update on Niraparib Development Strategy 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89

List of Tables
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2014 9
Number of Products under Development for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Comparative Analysis by Unknown Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd., H2 2014 18
Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corporation, H2 2014 19
Chemotherapy Induced Nausea and Vomiting - Pipeline by BioDelivery Sciences International, Inc., H2 2014 20
Chemotherapy Induced Nausea and Vomiting - Pipeline by Genovate Biotechnology Co., LTD., H2 2014 21
Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Holding S.A., H2 2014 22
Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics, Inc., H2 2014 23
Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics, Inc., H2 2014 24
Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 25
Chemotherapy Induced Nausea and Vomiting - Pipeline by Merck & Co., Inc., H2 2014 26
Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd., H2 2014 27
Chemotherapy Induced Nausea and Vomiting - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H2 2014 28
Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H2 2014 29
Chemotherapy Induced Nausea and Vomiting - Pipeline by Teikoku Pharma USA, Inc., H2 2014 30
Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro, Inc., H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Assessment by Combination Products, H2 2014 33
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 37
Number of Products by Stage and Route of Administration, H2 2014 39
Number of Products by Stage and Molecule Type, H2 2014 40
Chemotherapy Induced Nausea and Vomiting Therapeutics - Recent Pipeline Updates, H2 2014 64
Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2014 77
Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H2 2014 78